Every material Form 8-K CERUS CORP has filed with the SEC since July 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cerus reported third-quarter 2026 total revenue of $64.0 million, up 6% from a year earlier, with product revenue up 10% to $57.7 million. The net loss attributable to Cerus widened to $0.6 million from $0.02 million a year earlier, while the company reiterated its full-year 2026 product revenue guidance of $229 million to $231 million. The release also announced positive topline Phase 3 RedeS results for the INTERCEPT Blood System for red blood cells.
Total revenue was $64.0 million versus $60.2 million; product revenue was $57.7 million, up 10%.
Net loss attributable to Cerus was $0.6 million, or $0.00 per share, versus $0.02 million in the prior-year quarter.
Full-year 2026 product revenue guidance of $229 million to $231 million was reiterated, including IFC revenue of $23 million to $25 million.
Cash, cash equivalents and short-term investments were $57.1 million at September 30, 2026.
Cerus reported second-quarter 2026 total revenue of $63.3 million, up 5% from $60.1 million a year earlier, with product revenue up 10% to $57.4 million. The company narrowed its full-year 2026 product revenue guidance by raising the low end to $229 million to $231 million, and its net loss narrowed to $2.9 million, or $0.01 per share, from $5.7 million, or $0.03 per share, a year earlier.
Q2 2026 total revenue $63.3 million vs. $60.1 million in Q2 2025; product revenue $57.4 million, up 10%
Q2 2026 net loss attributable to Cerus $2.9 million ($0.01 per share) vs. $5.7 million ($0.03 per share) in Q2 2025
Product gross margin 51.4% vs. 55.2% a year earlier; company cites weaker U.S. dollar versus the Euro and higher product costs
2026 product revenue guidance now $229 million to $231 million, up from $227 million to $231 million; IFC guidance raised to $23 million to $25 million
Cerus said former CEO William "Obi" Greenman became Executive Chairman effective July 1, 2026, under an amendment to his employment letter dated July 6, 2026. The role runs through May 31, 2027, at roughly 60% of a full-time schedule, with a $500,000 base salary and no annual cash bonus eligibility for any part of 2027.
Greenman stepped down as President and CEO and became Executive Chairman effective July 1, 2026.
Executive Chairman term runs through May 31, 2027, unless ended earlier or extended in writing.
Base salary of $500,000; 2026 target annual cash bonus of 80% of base salary earned in 2026, with no bonus for any part of 2027.
Company will pay or reimburse COBRA premiums if his service makes him ineligible for group health coverage, subject to conditions.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CERUS CORP filing is on SEC EDGAR ↗. 8-K briefs of other companies →